Zacks Investment Research Upgrades Option Care Health (NASDAQ:OPCH) to Buy

Zacks Investment Research upgraded shares of Option Care Health (NASDAQ:OPCHGet Rating) from a hold rating to a buy rating in a research report sent to investors on Thursday, reports. Zacks Investment Research currently has $32.00 target price on the stock.

According to Zacks, “Option Care Health Inc provides infusion and home care management solutions. The Company offers products, services and condition-specific clinical management programs for gastrointestinal abnormalities, infectious diseases, cancer, organ and blood cell transplants, bleeding disorders and heart failures. Option Care Health Inc., formerly known as BioScrip Inc., is based in Denver, United States. “

Shares of Option Care Health stock opened at $29.45 on Thursday. Option Care Health has a fifty-two week low of $16.02 and a fifty-two week high of $30.32. The business’s fifty day simple moving average is $26.39. The company has a current ratio of 1.55, a quick ratio of 1.15 and a debt-to-equity ratio of 0.90. The stock has a market cap of $5.31 billion, a price-to-earnings ratio of 38.25, a PEG ratio of 1.44 and a beta of 1.38.

Option Care Health (NASDAQ:OPCHGet Rating) last released its earnings results on Wednesday, February 23rd. The company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.17. Option Care Health had a return on equity of 10.07% and a net margin of 4.07%. The firm had revenue of $927.19 million during the quarter, compared to analyst estimates of $917.68 million. During the same period in the prior year, the firm posted $0.10 earnings per share. The business’s quarterly revenue was up 15.2% compared to the same quarter last year. On average, analysts forecast that Option Care Health will post 0.93 EPS for the current fiscal year.

In related news, COO Harriet Booker sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 6th. The shares were sold at an average price of $27.18, for a total transaction of $163,080.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 18,000 shares of company stock worth $461,460 over the last three months. Corporate insiders own 47.00% of the company’s stock.

A number of hedge funds have recently bought and sold shares of OPCH. BlackRock Inc. raised its holdings in shares of Option Care Health by 4.6% in the 4th quarter. BlackRock Inc. now owns 16,586,493 shares of the company’s stock worth $471,721,000 after purchasing an additional 726,527 shares during the period. Park West Asset Management LLC raised its stake in shares of Option Care Health by 0.3% in the 3rd quarter. Park West Asset Management LLC now owns 6,043,475 shares of the company’s stock valued at $146,615,000 after acquiring an additional 15,710 shares during the period. State Street Corp lifted its holdings in shares of Option Care Health by 8.4% during the 4th quarter. State Street Corp now owns 4,406,306 shares of the company’s stock valued at $125,315,000 after acquiring an additional 341,158 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in Option Care Health by 45.6% during the 3rd quarter. UBS Asset Management Americas Inc. now owns 3,449,980 shares of the company’s stock worth $83,697,000 after purchasing an additional 1,080,002 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new stake in Option Care Health in the 4th quarter valued at $96,743,000. 97.80% of the stock is owned by hedge funds and other institutional investors.

Option Care Health Company Profile (Get Rating)

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

Featured Stories

Get a free copy of the Zacks research report on Option Care Health (OPCH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with's FREE daily email newsletter.